Last10K.com

Actinium Pharmaceuticals, Inc. (ATNM) SEC Filing 8-K Material Event for the period ending Saturday, February 18, 2023

Actinium Pharmaceuticals, Inc.

HISTORY TOOLS
CIK: 1388320 Ticker: ATNM

View differences made from one to another to evaluate Actinium Pharmaceuticals, Inc.'s financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Actinium Pharmaceuticals, Inc..

Continue

Assess how Actinium Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Actinium Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2023 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors

Continue

SEC Filing Tools

Financial Statements, Disclosures and Schedules

Inside this 8-K Corporate News

Cover

Material Contracts, Statements, Certifications & more

Actinium Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits

Exhibit 99.1: Press Release, Dated February 18, 2023
Exhibit 99.2: Investor Presentation, Dated February 18, 2023
Ticker: ATNM
CIK: 1388320
Form Type: 8-K Corporate News
Accession Number: 0001213900-23-013059
Submitted to the SEC: Tue Feb 21 2023 7:01:14 AM EST
Accepted by the SEC: Tue Feb 21 2023
Period: Saturday, February 18, 2023
Industry: Pharmaceutical Preparations
Events:
  1. Financial Exhibit
  2. Regulated Disclosure

External Resources:
Stock Quote
Social Media
SEC.gov

Bookmark the Permalink:
https://last10k.com/sec-filings/atnm/0001213900-23-013059.htm